54901-09-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,5-DIMETHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER is used as a synthetic reagent for the development of highly potent pan-fibroblast growth factor receptor (FGFR) inhibitors. These inhibitors play a crucial role in the treatment of various diseases, including cancer, by targeting the FGFR signaling pathway, which is often dysregulated in these conditions.
Used in Biochemical Research:
In the field of biochemical research, 3-(3,5-DIMETHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER is utilized as a reagent in the preparation of selective inhibitors of the FGFR tyrosine kinase. These inhibitors are essential tools for studying the function and regulation of FGFRs, which are involved in cell proliferation, differentiation, and migration. By selectively inhibiting these kinases, researchers can gain insights into the underlying mechanisms of diseases and identify potential therapeutic targets.
Used in Chemical Synthesis:
3-(3,5-DIMETHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER is also employed as an intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structural features make it a valuable building block for the development of novel molecules with diverse applications.

InChI:InChI=1/C13H18O4/c1-4-17-13(14)6-5-10-7-11(15-2)9-12(8-10)16-3/h7-9H,4-6H2,1-3H3

Upstream product

• 42174-79-8 (E)-ethyl 3-(3,5-dimethoxyphenyl)acrylate 
• 29584-64-3 ethyl 3,5-dimethoxycinnamate 
• 64-17-5 ethanol 
• 717-94-2 3-(3,5-dimethoxyphenyl)propionic acid 
• 7311-34-4 3,5-dimethoxybenzaldehdye 

Downstream Products

• 54901-10-9 4-(3,5-Dimethoxy-phenyl)-2-methyl-butan-2-ol 
• 1080-05-3 3-(3,5-dimethoxyphenyl)-1-propanol 
• 1000893-66-2 N₄-(3-(3,5-dimethoxyphenylethyl)-1H-pyrazol-5-yl)-N₂-((3-methylisoxazol-5-yl)methyl)pyrimidine-2,4-diamine 
• 1000895-53-3 3-(3,5-dimethoxyphenylethyl)-1H-pyrazol-5-amine 

Relevant academic research and scientific papers

Pyrazole derivative for FGFR inhibitor and preparation method of pyrazole derivative

The invention provides a pyrazole derivative for an FGFR inhibitor and a preparation method of the pyrazole derivative. The invention specifically relates to an amide pyrazole compound serving as an FGFR irreversible inhibitor, and a preparation method and application thereof. The present invention provides a compound as shown in Formula I, or a pharmaceutically acceptable salt, or solvate, isotope substitute, prodrug, or metabolite thereof. The compound as shown in general formula I have FGFR inhibitory activity, and is capable of preventing or treating disorders associated with FGFR activityor expression, preferably such as cancer.

Asymmetric total synthesis of dihydroisocoumarins: 6-methoxymellein, kigelin and fusarentin 6, 7 dimethyl ether by employing proline catalysed asymmetric α-aminoxylation

A concise asymmetric total synthesis of dihydroisocoumarins such as 6-methoxymellein, kigelin and fusarentin 6,7-dimethyl ether in high enantiopurity have been achieved from non-chiral aldehydes by employing proline catalysed asymmetric α-aminoxylation reaction. The required stereochemistry of hydroxyl group have been generated by alternating L or D proline as a organocatalyst in α-aminoxylation step and lactone ring is assembled by oxa-Pictet-Spengler cyclisation reaction as the key steps.

Vinyl sulfamido substituted pyrazolyl benzamide compound

The invention provides a vinyl sulfamide substituted pyrazolyl benzamide compound. Specifically, the present invention provides a compound in formula I shown in the specification or a pharmaceuticallyacceptable salt thereof, and a preparation method and use thereof. The compound shown in the formula I has excellent FGFR inhibitory activity and can be used for preventing or treating diseases related to FGFR kinase activity or expression quantity, such as cancer.

Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors

Fibroblast growth factor receptors (FGFRs) are important oncology targets due to the dysregulation of this signaling pathway in a wide variety of human cancers. We identified a series of pyrazolylaminoquinazoline derivatives as potent FGFR inhibitors with low nanomolar potency. The representative compound 29 strongly inhibited FGFR1-3 kinase activity and suppressed FGFR signaling transduction in FGFR-addicted cancer cells; FGFRs-driven cell proliferation was also strongly inhibited regardless of mechanistic complexity implicated in FGFR activation, which further confirmed that 29 was a potent pan-FGFR inhibitor. The flexibility of our structure offered the potential to preserve good affinity for mutant FGFR, which is important for developing TKIs with long-term efficacy.

A convenient and effective synthesis of 3-(3,5-dimethoxyphenyl)propanal

A convenient and effective synthesis of 3-(3,5-dimethoxyphenyl) propanal, an important intermediate in the synthesis of various biologically active compounds is described.